Aberrant HER3 Ligand Heregulin-Expressing Head and Neck Squamous Cell Carcinoma Is Resistant to Anti-Egfr Antibody Cetuximab, but Not Second-Generation EGFR-TKI

Oncogenesis - United States
doi 10.1038/s41389-019-0164-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2009English

EGFR Modulates Complement Activation in Head and Neck Squamous Cell Carcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View Beyond Cetuximab

Chemotherapy Research and Practice
2012English

Heregulin and HER3 Are Prognostic Biomarkers in Oropharyngeal Squamous Cell Carcinoma

Cancer
Cancer ResearchOncology
2015English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Overexpression of EGFR in Head and Neck Squamous Cell Carcinoma Is Associated With Inactivation of SH3GL2 and CDC25A Genes

PLoS ONE
Multidisciplinary
2013English

Detection of EGFR- And HER2-activating Mutations in Squamous Cell Carcinoma Involving the Head and Neck

Modern Pathology
Forensic MedicinePathology
2006English

When Is Chemotherapy in Head and Neck Squamous Cell Carcinoma Not Indicated?

European Archives of Oto-Rhino-Laryngology
MedicineOtorhinolaryngology
2014English

Co-Targeting EGFR and IKKβ/NF-κB Signalling Pathways in Head and Neck Squamous Cell Carcinoma: A Potential Novel Therapy for Head and Neck Squamous Cell Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy